Skip to content

Attorney advertising. TortMatics is a paid marketing service for participating law firms — not a law firm or lawyer referral service.

Information onlyReviewed Sep 23, 2026

Elmiron (pigmentary maculopathy)

Long-term use of Elmiron, a bladder-pain medication, has been tied to retinal damage in its FDA label. The federal case group is mostly resolved, so we provide information only.

Case group
MDL 2973
Court
D. New Jersey
Centralized
Dec 15, 2020
Pending cases
286Sep 1, 2026

We're not accepting review requests here

MDL 2973 is winding down (286 pending of 1,988 total) with ongoing confidential settlements.

See campaigns accepting reviews

Where things stand

  1. Jun 2020FDA approved label warning of pigmentary maculopathy with long-term use.
  2. Sep 1, 2026Pending actions down to 286 from 1,988 historical.

Records that usually help

You don't need these to start. Don't upload them here — a firm will ask if it needs them.

  • Pharmacy records for Elmiron
  • Retina/ophthalmology exam records, OCT imaging
  • Urology records for IC treatment
  • Vision-related impact documentation

About filing deadlines

Deadlines to file a claim vary by state and situation, and some may already have passed. Only a licensed attorney can tell you whether a deadline applies to you. Submitting here does not stop any deadline.

Attorney advertising. TortMatics (FusionByte Media LLC) is not a law firm. Information on this page is general and is not medical or legal advice. Talk to a doctor before changing any medication.